The dulaglutide biosimilar LY05008 demonstrated equivalent efficacy in reducing HbA1c, along with comparable safety and immunogenicity profiles, to the reference drug dulaglutide in Chinese adults ...

Skylar Jeremias is the Managing Editor for The Center for Biosimilars and The American Journal of Managed Care (AJMC).

Number 5: Global regulatory advancements in biosimilars enhance access to affordable treatments for autoimmune disorders, ...

Patients with rheumatoid and psoriatic arthritis maintained stable disease activity and functional capacity, with even some ...

Patent thickets hinder biosimilar access, driving up costs and delaying affordable treatments. Discover legislative solutions ...

Explore the evolving biosimilars landscape with expert insights on development, regulation, and global health harmonization ...

The Center for Biosimilars connects professionals with insights on biosimilars, health economics, regulatory outcomes, and emerging treatment paradigms.

CT-P6 demonstrates strong efficacy and safety in HER2-positive advanced gastric cancer, achieving an 82% disease control rate in real-world settings.

Global regulatory advancements in biosimilars enhance access to affordable treatments for autoimmune disorders, bone diseases ...

Explore the latest biosimilar developments, including legislative changes, new approvals, and challenges in understanding, shaping the future of affordable health care.

In the second setback this year for etanercept biosimilars, the US District Court for the District of New Jersey has ordered Samsung Bioepis to delay marketing Eticovo until 2029.